Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major

Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen S. Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important. Design and Methods Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3rd year, allowing cardiac iron removal to be analyzed over three years. Results Mean deferasirox dose during year 3 was 33.6±9.8 mg/kg per day. Myocardial T2*, assessed by cardiovascular magnetic resonance, significantly increased from 12.0 ms ±39.1% at baseline to 17.1 ms ±62.0% at end of study (P5 to

Original languageEnglish
Pages (from-to)842-848
Number of pages7
JournalHaematologica
Volume97
Issue number6
DOIs
Publication statusPublished - Jun 1 2012

Fingerprint

beta-Thalassemia
Iron
Magnetic Resonance Spectroscopy
deferasirox

Keywords

  • β-thalassemia major
  • Deferasirox
  • Iron chelation
  • Myocardial T2

ASJC Scopus subject areas

  • Hematology

Cite this

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. / Pennell, Dudley J.; Porter, John B.; Cappellini, Maria Domenica; Chan, Lee Lee; El-Beshlawy, Amal; Aydinok, Yesim; Ibrahim, Hishamshah; Li, Chi Kong; Viprakasit, Vip; Elalfy, Mohsen S.; Kattamis, Antonis; Smith, Gillian; Habr, Dany; Domokos, Gabor; Roubert, Bernard; Taher, Ali.

In: Haematologica, Vol. 97, No. 6, 01.06.2012, p. 842-848.

Research output: Contribution to journalArticle

Pennell, DJ, Porter, JB, Cappellini, MD, Chan, LL, El-Beshlawy, A, Aydinok, Y, Ibrahim, H, Li, CK, Viprakasit, V, Elalfy, MS, Kattamis, A, Smith, G, Habr, D, Domokos, G, Roubert, B & Taher, A 2012, 'Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major', Haematologica, vol. 97, no. 6, pp. 842-848. https://doi.org/10.3324/haematol.2011.049957
Pennell, Dudley J. ; Porter, John B. ; Cappellini, Maria Domenica ; Chan, Lee Lee ; El-Beshlawy, Amal ; Aydinok, Yesim ; Ibrahim, Hishamshah ; Li, Chi Kong ; Viprakasit, Vip ; Elalfy, Mohsen S. ; Kattamis, Antonis ; Smith, Gillian ; Habr, Dany ; Domokos, Gabor ; Roubert, Bernard ; Taher, Ali. / Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. In: Haematologica. 2012 ; Vol. 97, No. 6. pp. 842-848.
@article{63d111dd8d0f47f7a9e7cffce1dd5a10,
title = "Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major",
abstract = "Background Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important. Design and Methods Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3rd year, allowing cardiac iron removal to be analyzed over three years. Results Mean deferasirox dose during year 3 was 33.6±9.8 mg/kg per day. Myocardial T2*, assessed by cardiovascular magnetic resonance, significantly increased from 12.0 ms ±39.1{\%} at baseline to 17.1 ms ±62.0{\%} at end of study (P5 to",
keywords = "β-thalassemia major, Deferasirox, Iron chelation, Myocardial T2",
author = "Pennell, {Dudley J.} and Porter, {John B.} and Cappellini, {Maria Domenica} and Chan, {Lee Lee} and Amal El-Beshlawy and Yesim Aydinok and Hishamshah Ibrahim and Li, {Chi Kong} and Vip Viprakasit and Elalfy, {Mohsen S.} and Antonis Kattamis and Gillian Smith and Dany Habr and Gabor Domokos and Bernard Roubert and Ali Taher",
year = "2012",
month = "6",
day = "1",
doi = "10.3324/haematol.2011.049957",
language = "English",
volume = "97",
pages = "842--848",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major

AU - Pennell, Dudley J.

AU - Porter, John B.

AU - Cappellini, Maria Domenica

AU - Chan, Lee Lee

AU - El-Beshlawy, Amal

AU - Aydinok, Yesim

AU - Ibrahim, Hishamshah

AU - Li, Chi Kong

AU - Viprakasit, Vip

AU - Elalfy, Mohsen S.

AU - Kattamis, Antonis

AU - Smith, Gillian

AU - Habr, Dany

AU - Domokos, Gabor

AU - Roubert, Bernard

AU - Taher, Ali

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important. Design and Methods Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3rd year, allowing cardiac iron removal to be analyzed over three years. Results Mean deferasirox dose during year 3 was 33.6±9.8 mg/kg per day. Myocardial T2*, assessed by cardiovascular magnetic resonance, significantly increased from 12.0 ms ±39.1% at baseline to 17.1 ms ±62.0% at end of study (P5 to

AB - Background Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important. Design and Methods Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3rd year, allowing cardiac iron removal to be analyzed over three years. Results Mean deferasirox dose during year 3 was 33.6±9.8 mg/kg per day. Myocardial T2*, assessed by cardiovascular magnetic resonance, significantly increased from 12.0 ms ±39.1% at baseline to 17.1 ms ±62.0% at end of study (P5 to

KW - β-thalassemia major

KW - Deferasirox

KW - Iron chelation

KW - Myocardial T2

UR - http://www.scopus.com/inward/record.url?scp=84862141974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862141974&partnerID=8YFLogxK

U2 - 10.3324/haematol.2011.049957

DO - 10.3324/haematol.2011.049957

M3 - Article

C2 - 22271905

AN - SCOPUS:84862141974

VL - 97

SP - 842

EP - 848

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -